AMG National Trust Bank Has $2.53 Million Stake in Amgen, Inc. (AMGN)
AMG National Trust Bank decreased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 13,313 shares of the medical research company’s stock after selling 575 shares during the period. AMG National Trust Bank’s holdings in Amgen were worth $2,529,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. BKD Wealth Advisors LLC grew its position in Amgen by 3.9% during the 4th quarter. BKD Wealth Advisors LLC now owns 4,032 shares of the medical research company’s stock worth $785,000 after purchasing an additional 150 shares during the last quarter. Trust Co. of Toledo NA OH grew its position in Amgen by 11.6% during the 4th quarter. Trust Co. of Toledo NA OH now owns 11,546 shares of the medical research company’s stock worth $2,248,000 after purchasing an additional 1,197 shares during the last quarter. Osborn Williams & Donohoe LLC grew its position in Amgen by 2.4% during the 4th quarter. Osborn Williams & Donohoe LLC now owns 25,359 shares of the medical research company’s stock worth $4,937,000 after purchasing an additional 599 shares during the last quarter. Leavell Investment Management Inc. grew its position in Amgen by 1.6% during the 4th quarter. Leavell Investment Management Inc. now owns 10,640 shares of the medical research company’s stock worth $2,071,000 after purchasing an additional 169 shares during the last quarter. Finally, First Command Financial Services Inc. grew its position in Amgen by 54.5% during the 4th quarter. First Command Financial Services Inc. now owns 2,411 shares of the medical research company’s stock worth $469,000 after purchasing an additional 850 shares during the last quarter. 77.31% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ AMGN opened at $166.70 on Monday. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $210.19. The company has a market cap of $103.10 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 2.23 and a beta of 1.15.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the sale, the director now directly owns 15,092 shares in the company, valued at approximately $2,915,472.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 6,000 shares of company stock valued at $1,115,580. Company insiders own 0.25% of the company’s stock.
AMGN has been the topic of several research analyst reports. BMO Capital Markets initiated coverage on shares of Amgen in a research report on Thursday, March 14th. They set an “outperform” rating and a $228.00 target price on the stock. Mizuho set a $208.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Monday, April 22nd. Cowen reissued a “buy” rating and set a $229.00 target price on shares of Amgen in a research report on Wednesday, May 1st. Cantor Fitzgerald reissued a “hold” rating and set a $221.00 target price on shares of Amgen in a research report on Monday, April 1st. Finally, JPMorgan Chase & Co. reissued a “hold” rating and set a $190.00 target price on shares of Amgen in a research report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $208.35.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/amg-national-trust-bank-has-2-53-million-stake-in-amgen-inc-amgn/3029826.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: How a Put Option Works
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.